NASDAQ:BTAI BioXcel Therapeutics (BTAI) Stock Price, News & Analysis $1.13 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.15 +0.02 (+1.42%) As of 05/22/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About BioXcel Therapeutics Stock (NASDAQ:BTAI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioXcel Therapeutics alerts:Sign Up Key Stats Today's Range$1.13▼$1.1850-Day Range$1.02▼$1.7352-Week Range$1.01▼$8.08Volume348,912 shsAverage Volume629,650 shsMarket Capitalization$34.89 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingHold Company Overview BioXcel Therapeutics, Inc. is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes. BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option. ZYESAMI® (aviptadil) is authorized for the treatment of acute respiratory distress syndrome, including in patients with critical COVID-19–related respiratory failure, representing the company’s expansion into critical care medicine. In addition to its marketed products, BioXcel maintains a diversified pipeline of clinical and preclinical programs targeting neuropsychiatric and immuno-oncology indications. The company collaborates with academic institutions and strategic partners to further validate its AI-identified assets and explore new indications, underpinning its strategy to deliver differentiated treatments across multiple therapeutic areas. Founded in 2017 and headquartered in New Haven, Connecticut, BioXcel Therapeutics completed its public listing in 2019. The company currently serves the U.S. market and is evaluating opportunities for global expansion. Under the leadership of President and CEO Vimal Mehta, M.D., Ph.D., BioXcel is focused on growing its commercial footprint and advancing its AI-enabled pipeline toward key regulatory milestones.AI Generated. May Contain Errors. Read More BioXcel Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreBTAI MarketRank™: BioXcel Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 611th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingHold Consensus RatingBioXcel Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialBioXcel Therapeutics has a consensus price target of $11.00, representing about 873.5% upside from its current price of $1.13.Amount of Analyst CoverageBioXcel Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about BioXcel Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BioXcel Therapeutics are expected to grow in the coming year, from ($2.07) to ($1.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioXcel Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioXcel Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BioXcel Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.28% of the float of BioXcel Therapeutics has been sold short.Short Interest Ratio / Days to CoverBioXcel Therapeutics has a short interest ratio ("days to cover") of 4.78.Change versus previous monthShort interest in BioXcel Therapeutics has recently increased by 7.52%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioXcel Therapeutics does not currently pay a dividend.Dividend GrowthBioXcel Therapeutics does not have a long track record of dividend growth. News and Social Media1.0 / 5News Sentiment-0.35 News SentimentBioXcel Therapeutics has a news sentiment score of -0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for BioXcel Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 10 people have searched for BTAI on MarketBeat in the last 30 days. This is a decrease of -23% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, BioXcel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $43,037.00 in company stock.Percentage Held by Insiders3.70% of the stock of BioXcel Therapeutics is held by insiders.Percentage Held by Institutions30.68% of the stock of BioXcel Therapeutics is held by institutions.Read more about BioXcel Therapeutics' insider trading history. Receive BTAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BTAI Stock News HeadlinesBioXcel Therapeutics (NASDAQ:BTAI) CEO Sells $21,166.71 in StockMay 23 at 9:10 AM | insidertrades.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives Consensus Recommendation of "Hold" from AnalystsMay 20, 2026 | americanbankingnews.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.May 25 at 1:00 AM | Profits Run (Ad)BioXcel Therapeutics (NASDAQ:BTAI) Stock Rating Lowered by Wall Street ZenMay 16, 2026 | americanbankingnews.comBioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial ResultsMay 15, 2026 | globenewswire.comBioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home SettingApril 18, 2026 | markets.businessinsider.comH.C. Wainwright Adjusts BioXcel Therapeutics, Inc. (BTAI) Outlook Following Capital Structure ConcernsApril 18, 2026 | finance.yahoo.comBioxcel Issues Warrants in Private Equity Financing DealApril 17, 2026 | tipranks.comSee More Headlines BTAI Stock Analysis - Frequently Asked Questions How have BTAI shares performed this year? BioXcel Therapeutics' stock was trading at $1.60 at the beginning of 2026. Since then, BTAI shares have decreased by 29.4% and is now trading at $1.13. How were BioXcel Therapeutics' earnings last quarter? BioXcel Therapeutics, Inc. (NASDAQ:BTAI) issued its quarterly earnings results on Friday, May, 15th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by $0.01. The firm earned $0.21 million during the quarter, compared to the consensus estimate of $0.38 million. When did BioXcel Therapeutics' stock split? BioXcel Therapeutics shares reverse split before market open on Monday, February 10th 2025.The 1-16 reverse split was announced on Thursday, February 6th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2025. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did BioXcel Therapeutics IPO? BioXcel Therapeutics (BTAI) raised $65 million in an initial public offering (IPO) on Thursday, March 8th 2018. The company issued 5,454,545 shares at a price of $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager. How do I buy shares of BioXcel Therapeutics? Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioXcel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioXcel Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD), Adobe (ADBE) and Saia (SAIA). Company Calendar Last Earnings5/15/2026Today5/25/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 BTAI's financial health is in the Red zone, according to TradeSmith. BTAI has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BTAI CIK1720893 Webwww.bioxceltherapeutics.com Phone(475) 238-6837FaxN/AEmployees90Year Founded2017Price Target and Rating Average Price Target for BioXcel Therapeutics$11.00 High Price Target$17.00 Low Price Target$5.00 Potential Upside/Downside+873.5%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($5.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$69.90 million Net Margins-11,078.53% Pretax Margin-11,078.53% Return on EquityN/A Return on Assets-201.53% Debt Debt-to-Equity RatioN/A Current Ratio0.62 Quick Ratio0.82 Sales & Book Value Annual Sales$640 thousand Price / Sales54.52 Cash FlowN/A Price / Cash FlowN/A Book Value($3.42) per share Price / Book-0.33Miscellaneous Outstanding Shares30,880,000Free Float29,736,000Market Cap$34.89 million OptionableNo Data Beta0.31 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:BTAI) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
